Skip to content
Maimon Research LLC

  • Home
  • Publications
  • Working Papers
  • WYOMING CERTIFICATE PROGRAM
  • Australian PBAC HTA Review
  • Wyoming PHCY 5141
Latest Working Papers

Mapping Impossible Utilities: The ICER report on Tezepelumab for severe asthma.

November 22, 2021 Dr Paul Langely 565 Views

Paul C. Langley, Ph.D., Adjunct Professor College of Pharmacy, University of Minnesota, MN

The Maimon Working Papers are free to download (in PDF format) at the bottom of the page.
Working-Paper-No.-22-November-2021Download
  • Inventing Imaginary Claims and Recommendations for Pricing with Mavacamten in Symptomatic Hypertrophic Cardiomyopathy (SHCM) by the Institute for Clinical and Economic
  • Another Imaginary ICER Future: Assumption driven invented claims for Tirzepatide in Type 2 Diabetes

Key Links

  • Australian PBAC HTA Review
  • Publications 2017- 2023
  • Latest Working Papers
  • Nonsense on Stilts
  • Assumptions and Models
  • Fundamental Measurement
  • The Mystical Viral QALY
  • ICER Fantasy
  • Tufts' Ordinal Oversight
  • Cheers 22 Meets Catch 22
  • False Claims
  • Paper Mills
  • Rare Diseases
  • Rasch Value Claims
  • Morisky Adherence

Latest Publications

Langley PC. Nothing to Cheer About: Endorsing  Imaginary Economic Evaluations and Value Claims with CHEERS 22 [version 1; peer review: awaiting peer review]

Abstract

One of the more unfortunate features of health technology assessment is the tenacity with which leaders in the field and organizations such as the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Institute for Clinical and Economic Review (ICER) cling to an evaluation framework that fails to meet the standards of normal science.

Copyright © 2025 Maimon Research LLC. All rights reserved.
Privacy Policy